Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.

Marwah Al-Aloosi¹, Amanda M Prechtl¹, Payel Chatterjee¹, Brady Bernard^1,2, Christopher J Kemp³, Rachele Rosati¹, Robert L Diaz¹, Lauren R Appleyard¹, Shalini Pereira¹, Alex Rajewski¹, Amber McDonald⁴, Eva J Gordon⁴, Carla Grandori¹

¹SEngine Precision Medicine, Seattle, WA, United States.

²Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States.

³Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, United States.

⁴Private Health Management, Los Angeles, CA, United States.

PubMed PMC DOI PDF

Abstract

Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance often develops. Toxic side effects along with disease progression render patients unable to receive additional lines of treatment and limit their opti…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.